Table 1.
Baseline data
| Index | Research group (n=45) | Control group (n=44) | χ2/t | P |
|---|---|---|---|---|
| Sex | 0.542 | 0.461 | ||
| Male | 29 | 25 | ||
| Female | 16 | 19 | ||
| Age (years) | 68.8±5.4 | 69.1±4.8 | 0.277 | 0.782 |
| BMI (kg/m2) | 23.66±3.20 | 23.10±3.65 | 0.769 | 0.444 |
| Course of disease (years) | 12.0±3.9 | 12.3±3.4 | 0.387 | 0.700 |
| Hypertension risk grading (n) | 0.750 | 0.687 | ||
| I | 13 | 12 | ||
| II | 25 | 22 | ||
| III | 7 | 10 | ||
| Type of antihypertensive drug (n) | 0.637 | 0.412 | ||
| ACEI | 21 | 17 | ||
| ARB | 15 | 15 | ||
| Calcium antagonists | 12 | 14 | ||
| β-blocker | 10 | 11 | ||
| Central antihypertensive drug | 13 | 10 | ||
| Others | 7 | 9 | ||
| Combination therapy (n) | 0.142 | 0.706 | ||
| Double combinations | 15 | 12 | ||
| Triple combinations | 10 | 10 | ||
| Complication | 0.245 | 0.621 | ||
| Hyperlipidemia | 24 | 25 | ||
| Diabetes | 18 | 15 | ||
| Smoking (n) | 0.275 | 0.600 | ||
| Yes | 14 | 16 | ||
| No | 31 | 28 | ||
| Drinking (n) | 1.112 | 0.292 | ||
| Yes | 10 | 6 | ||
| No | 35 | 38 |
Note: BMI: body mass index; ACEI: angiotension converting enzyme inhibitors; ARB: angiotensin receptor blocker.